The overall aim of the SCIENCE project is to implement an effective stem cell-based therapy with allogeneic adipose derived stromal cells to improve myocardial function in patients with IHD and heart failure.
This will be achieved by conducting a multicentre clinical trial in a consortium of experienced international scientists as well as significant representatives of the biomedical industry within translational medicine and a close collaboration with relevant authorities.
With more than 17 million deaths worldwide each year, ischemic heart disease (IHD) caused by coronary artery disease is the most common cause of death and a major cause of hospital admissions in industrialised countries. IHD caused over four million deaths in Europe in the year 2012 constituting 47% of all deaths.
Conventional therapies have reduced mortality of IHD significantly, but have left an increasing number of patients with chronic IHD and/or heart failure without further treatment options. An increasing morbidity rate of this nature in an ageing population is a huge burden for society.The consortium will ensure feasibility of treatment by simplifying cell production and distribution to make cell therapy a realistic option for clinical practise.
The consortium expects the SCIENCE project to pave the way for future approval of this treatment by national authorities throughout Europe as the standard form of care for patients with ischemic heart disease and heart failure.
MedUni Vienna Researchers
The Medical University of Vienna is the project coordinator under the leadership of Assoc.-Prof.in Univ.-Doz.in Dr.in Mariann Pavone-Gyöngyösi, Department of Medicine II, Division of Cardiology.
Prof.in Dr.in Irene Lang
Mag. Dr. Alfred Gugerell
Katrin Zlabinger, MSc
Coordinator: Prof. MD DMSc Jens Kastrup, Department of Cardiology Rigshospitalet Copenhagen University, Denmark
10 project participants
|Project duration||01.01.2015 - 01.01.2020|
|EU contribution - MedUni Vienna||421.875 €|
|EC contribution - total project||5.998.882 €|